Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective

William E Boden, Marcus D Flather, Deepak L Bhatt

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial has spurred debate over subgroup analysis interpretation and prompted renewed consideration of the long-term role of dual aspirin and clopidogrel therapy (DAPT) in patients with established vascular disease.
Original languageEnglish
Pages (from-to)207-16
Number of pages10
JournalCardiovascular Drugs and Therapy
Volume24
Issue number3
DOIs
Publication statusPublished - Jun 2010

Keywords

  • Aspirin
  • Hemorrhage
  • Humans
  • Platelet Aggregation Inhibitors
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Risk
  • Thrombosis
  • Ticlopidine
  • Time Factors
  • Vascular Diseases

Cite this